Current Cancer Drug Targets
Volume 20, 11 Issues, 2020
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
  |
In the current pandemic scenario, publication process of all articles related to Coronavirus will be expedited, for timely publication of much needed research
Contents
Current Cancer Drug Targets, Volume 10 - Number 2
ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
, 10(2): 127 - 134S. Micuda, D. Rosel, A. Ryska and J. Brabek
DOI: 10.2174/156800910791054202
Understanding FOXO, New Views on Old Transcription Factors
, 10(2): 135 - 146F. Zanella, W. Link and A. Carnero
DOI: 10.2174/156800910791054158
Pharmacological Modulation of Genome and Proteome Alterations in Mice Treated with the Endocrine Disruptor Bisphenol A
, 10(2): 147 - 154A. Izzotti, M. Longobardi, C. Cartiglia, F. D'Agostini, S. Kanitz and S. De Flora
DOI: 10.2174/156800910791054220
Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
, 10(2): 155 - 167A. K. Gandhi, J. Kang, L. Capone, A. Parton, L. Wu, L. H. Zhang, D. Mendy, A. Lopez-Girona, T. Tran, L. Sapinoso, W. Fang, S. Xu, G. Hampton, J. B. Bartlett and P. Schafer
DOI: 10.2174/156800910791054239
Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition
, 10(2): 168 - 175G. Zoppoli, E. Moran, D. Soncini, M. Cea, A. Garuti, I. Rocco, G. Cirmena, V. Grillo, L. Bagnasco, G. Icardi, F. Ansaldi, S. Parodi, F. Patrone, A. Ballestrero and A. Nencioni
DOI: 10.2174/156800910791054211
Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation
, 10(2): 176 - 191R. E. Favoni, A. Pattarozzi, M. Lo Casto, F. Barbieri, M. Gatti, L. Paleari, A. Bajetto, C. Porcile, G. Gaudino, L. Mutti, G. Corte, T. Florio and M. Casto
DOI: 10.2174/156800910791054130
Structure-Activity Studies on Arylamides and Arysulfonamides Ras Inhibitors
, 10(2): 192 - 199S. Colombo, A. Palmioli, C. Airoldi, R. Tisi, S. Fantinato, S. Olivieri, L. De Gioia, E. Martegani and F. Peri
DOI: 10.2174/156800910791054185
Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
, 10(2): 200 - 209F. Navid, V. M. Santana and R. C. Barfield
DOI: 10.2174/156800910791054167
Inhibitors of HDACs - Effective Drugs Against Cancer?
, 10(2): 210 - 228S. Muller and O. H. Kramer
DOI: 10.2174/156800910791054149
Antitumor Effect of Butanoylated Heparin with Low Anticoagulant Activity on Lung Cancer Growth in Mice and Rats
, 10(2): 229 - 241Lunyin Yu, Hari G. Garg, Boyangzi Li, Robert J. Linhardt and Charles A. Hales
DOI: 10.2174/156800910791054176
The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery
, 10(2): 242 - 267M. Hingorani, C. Spitzweg, G. Vassaux, K. Newbold, A. Melcher, H. Pandha, R. Vile and K. Harrington
DOI: 10.2174/156800910791054194
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)
View Full Editorial Board
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
View Full Editorial Board
About the Journal
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.
Scopus CiteScore Metrics: 2.75
Advertisement
Webmaster Contact: info@benthamscience.net